Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria

The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes F...

Descripción completa

Detalles Bibliográficos
Autores: Kaplan, Allen P., Giménez Arnau, Anna Maria, Saini, Sarbjit S.
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2017
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/33197
Acceso en línea:http://hdl.handle.net/10230/33197
http://dx.doi.org/10.1111/all.13083
Access Level:acceso abierto
Palabra clave:Urticària -- Tractament
chronic idiopathic urticaria
Chronic spontaneous urticaria
Omalizumab
id ES_4d2ed447a3b7acebfac14c77e8c8bac9
oai_identifier_str oai:recercat.cat:10230/33197
network_acronym_str ES
network_name_str España
repository_id_str
spelling Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticariaKaplan, Allen P.Giménez Arnau, Anna MariaSaini, Sarbjit S.Urticària -- Tractamentchronic idiopathic urticariaChronic spontaneous urticariaOmalizumabThe monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.Wiley20172017info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/33197http://dx.doi.org/10.1111/all.13083reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAllergy. 2017 Apr;72(4):519-33This is the peer reviewed version of the following article: Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr;72(4):519-533, which has been published in final form at http://dx.doi.org/10.1111/all.13083. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.info:eu-repo/semantics/openAccessoai:recercat.cat:10230/331972026-05-29T05:05:01Z
dc.title.none.fl_str_mv Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
title Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
spellingShingle Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Kaplan, Allen P.
Urticària -- Tractament
chronic idiopathic urticaria
Chronic spontaneous urticaria
Omalizumab
title_short Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
title_full Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
title_fullStr Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
title_full_unstemmed Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
title_sort Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
dc.creator.none.fl_str_mv Kaplan, Allen P.
Giménez Arnau, Anna Maria
Saini, Sarbjit S.
author Kaplan, Allen P.
author_facet Kaplan, Allen P.
Giménez Arnau, Anna Maria
Saini, Sarbjit S.
author_role author
author2 Giménez Arnau, Anna Maria
Saini, Sarbjit S.
author2_role author
author
dc.subject.none.fl_str_mv Urticària -- Tractament
chronic idiopathic urticaria
Chronic spontaneous urticaria
Omalizumab
topic Urticària -- Tractament
chronic idiopathic urticaria
Chronic spontaneous urticaria
Omalizumab
description The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically 'abnormal' IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/33197
http://dx.doi.org/10.1111/all.13083
url http://hdl.handle.net/10230/33197
http://dx.doi.org/10.1111/all.13083
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Allergy. 2017 Apr;72(4):519-33
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407675330068480
score 15,812429

Similares en LA Referencia